Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551 on ClinicalTrials.gov · last registry update 2022-03-25

Finished 25 May 2018, after enrolling 514 people. Primary outcome, as filed: Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 26: Core Period. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Sanofi
Sponsor type: Industry
Enrollment: 514
Started: 2016-07-06
Primary completion: 2018-05-25 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 26: Core Period

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.